Table 4.

The subgroups analysis for lincRNA-ROR and DFS in cancer patients.

					Pooled Data			Test for Heterogeneity
Subgroups	Number of Studies	Case (n)	High expression (n)	High expression (%)	HR	95% CI	P-value	P-value	I2 (%)
Univariate analysis
Histological type
Digestive cancer	3	268	140	52.2	2.96	1.24–7.07	.015	.001	86.2
Other cancer	1	229	113	49.3	1.82	1.25–2.65	.002	–	–
Case (n)
< 100	2	148	76	51.4	4.38	1.28–15.01	.019	.015	83.0
≥ 100	2	349	177	50.7	1.66	1.30–2.13	<.001	.531	0.0
Follow-up (mo)
≤ 60	3	437	221	50.6	1.76	1.40–2.21	<.001	.426	0.0
> 60	1	60	32	53.3	8.51	3.73–19.42	< .001	–	–
Multivariate analysis
Histological type
Digestive cancer	2	180	96	53.3	3.45	1.97–6.04	<.001	.295	8.9
Other cancer	1	229	113	49.3	3.42	1.59–7.36	.002	–	–
Case (n)
< 100	1	60	32	53.3	5.64	1.92–16.57	.002	–	–
≥ 100	2	349	177	50.7	3.10	1.94–4.94	<.001	.751	0.0
Follow-up (mo)
≤ 60	2	349	177	50.7	3.10	1.94–4.94	<.001	.751	0.0
> 60	1	60	32	53.3	5.64	1.92–16.57	.002	–	–

CI = confidence interval, DFS = disease-free survival, HR = hazard ratio, LincRNA-ROR = Large intergenic noncoding RNA regulator of reprogramming.